51 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B Sell
Article Searches
GlaxoSmithKline (GSK) Flat As Market Gains: What You Should Know http://www.zacks.com/stock/news/351676/glaxosmithkline-gsk-flat-as-market-gains-what-you-should-know?cid=CS-ZC-FT-351676 Feb 01, 2019 - GlaxoSmithKline (GSK) closed at $39.20 in the latest trading session, marking no change from the prior day.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203 Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Top Ranked Income Stocks to Buy for February 14th http://www.zacks.com/commentary/213612/top-ranked-income-stocks-to-buy-for-february-14th?cid=CS-ZC-FT-213612 Feb 14, 2019 - Top Ranked Income Stocks to Buy for February 14th
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/354603/astrazenecas-azn-q4-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-354603 Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B http://www.zacks.com/stock/news/354868/johnson-johnson-jnj-to-acquire-auris-health-for-%2434b?cid=CS-ZC-FT-354868 Feb 14, 2019 - Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo http://www.zacks.com/stock/news/355437/bayer-obtains-full-rights-to-vitrakvi-from-lillys-loxo?cid=CS-ZC-FT-355437 Feb 19, 2019 - Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.
Merck Gets Priority Review for Keytruda in Third-Line SCLC http://www.zacks.com/stock/news/355982/merck-gets-priority-review-for-keytruda-in-third-line-sclc?cid=CS-ZC-FT-355982 Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Top Ranked Income Stocks to Buy for February 22nd http://www.zacks.com/commentary/215702/top-ranked-income-stocks-to-buy-for-february-22nd?cid=CS-ZC-FT-215702 Feb 22, 2019 - Top Ranked Income Stocks to Buy for February 22nd
The Zacks Analyst Blog Highlights: Boeing, GlaxoSmithKline and Rio Tinto http://www.zacks.com/stock/news/356964/the-zacks-analyst-blog-highlights-boeing-glaxosmithkline-and-rio-tinto?cid=CS-ZC-FT-356964 Feb 26, 2019 - The Zacks Analyst Blog Highlights: Boeing, GlaxoSmithKline and Rio Tinto
Top Ranked Income Stocks to Buy for February 27th http://www.zacks.com/commentary/216784/top-ranked-income-stocks-to-buy-for-february-27th?cid=CS-ZC-FT-216784 Feb 27, 2019 - Top Ranked Income Stocks to Buy for February 27th

Pages: 123456

Page 1>